Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > LATEST
LATEST
-
BUSINESS Eylea Bio-AG to Carry DME Indication Missing from Fuji’s Biosimilar Label
December 5, 2025
-
BUSINESS Forxiga Generics Launch in Japan at 33.6% of Originator Price: Sawai, T’s Pharma
December 5, 2025
-
BUSINESS Vimpat Copies Hit Shelves at 35% of Originator Price as 10 Firms Flock to Market
December 5, 2025
-
REGULATORY LDP, Ishin to Continue OTC-Like Drug Talks on “Special Charge” Design
December 5, 2025
-
REGULATORY Forxiga, Zytiga Seen Taking Biggest Hit by PMP Returns in FY2026
December 5, 2025
-
BUSINESS Keytruda Extends Japan Sales Lead to 26 Straight Months in November: Encise
December 5, 2025
-
REGULATORY Vimpat Draws 10 Generic Entrants in December Listing; Forxiga Has Two, but Nipro AG Absent
December 4, 2025
-
REGULATORY MHLW Floats Deducting Private-Practice Use for Re-Pricing, but Off-Cycle Cuts Possible; GLP-1 Eyed?
December 4, 2025
-
REGULATORY Bayer’s Eylea Bio-AG Finally Reaches NHI Listing amid Reform Talks
December 4, 2025
-
REGULATORY MHLW Panel Green-Lights Approval for Kissei’s Uterine Fibroid Drug, 3 More NMEs
December 4, 2025
-
REGULATORY MHLW Proposes Pricing New AGs and Bio-AGs on Par with Originators
December 4, 2025
-
REGULATORY FY2026 Reform Roadmap Keeps Key Drug Pricing Issues on Ice, Snubs Many Industry Requests: Chuikyo
December 4, 2025
-
BUSINESS Novo Nordisk Launches Higher-Capacity Awiqli Pen in Japan
December 4, 2025
-
BUSINESS Daiichi Sankyo Wins US Appeal in Seagen ADC Patent Dispute
December 4, 2025
-
BUSINESS Vimpat Generics Win Added Use, Clearing Path for Full-Label Launch
December 4, 2025
-
REGULATORY LDP Tax Panel Puts R&D Tax Credit on Political-Judgment Track for Further Talks
December 3, 2025
-
ORGANIZATION Labor Union Group Submits Request, Urges Drug Pricing Overhaul amid Inflation
December 3, 2025
-
REGULATORY Average NHI-Market Price Gap Hits Fresh Record Low at 4.8%
December 3, 2025
-
REGULATORY MOF Panel Submits Budget Proposal, Urges Wider CEA Use and More Frequent Re-Pricing
December 3, 2025
-
BUSINESS Alfresa, CMIC Ink Pact to Build Vaccination Support Platform
December 3, 2025
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…